RUNX1-FPD (also known as RUNX1-FPDMM or FPD-AML) is a rare inherited disease caused by a mutation in the RUNX1 gene, resulting in lower blood platelet counts, platelet dysfunction, and an increased risk of early-onset blood cancers. Individuals with this disease primarily develop acute myeloid leukemia (AML), the second deadliest blood cancer.

RUNX1-FPD patients often face a range of health issues including asthma, allergies, autoimmune disorders and gastrointestinal problems. Discovered in 1999, this disease varies greatly between families, even within families, with some having a significantly higher incidence of blood cancer development.